An investigation for investors in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals was announced.

San Diego, CA -- (SBWire) -- 09/27/2017 --An investigation was announced for investors in NASDAQ:ALNY shares over potential securities laws violations by Alnylam Pharmaceuticals in connection with certain financial statements.

Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether certain statements by Alnylam Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambrdige, MA based Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $41.10 million in 2015 to $47.16 million in 2016 and that its Net loss increased from $290.07 million in 2015 to $410.11 million in 2016. Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew from $31.41 per share in late 2016 to as high as $89.29 per share on September 1, 2017.

On September 7, 2017, Alnylam Pharmaceuticals, Inc. advised investors that the Company had stop giving doses of fitusiran, Alnylam's experimental hemophilia treatment, to patients enrolled in the Company's clinical studies, following the death of a patient who developed a blood clot. Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) declined on September 8, 2017 to $70.92 per share.

Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com